Accurate immunohistochemical evaluation of folate receptor alpha (FOLR1) expression is critical for identifying patients with ovarian carcinoma who may benefit from targeted therapy with Mirvetuximab Soravtansine. Here, FOLR1 is linked to ovarian carcinoma.